All In MedTech

Device Trial Radar · NCT04326946

International Alfapump Cohort Study

International Alfapump Cohort Study: in Patients With Refractory Ascites Due to Liver Cirrhosis or Malignant Ascites With a Life Expectancy of 6 Months or Less

Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 14, 2018

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Sequana Medical N.V.Not on our public-company list
Sponsor type
Industry
First posted
Mar 30, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes

Summary

As written by the sponsor on the registry.

This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.

Conditions

  • Liver Cirrhoses
  • Malignant Ascites

Interventions

  • AlfapumpDevice

    alfapump implementation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient survival at 6 months post implantTime frame: 6 months post-implant

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Universitätsklinikum Leipzig

    Leipzig, Germany

  • Inselspital

    Bern, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.